MAM
ACRS icon

Meeder Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

Meeder Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,383
Closed -$43K – 1104
2021
Q3 		$43K Buy
+2,383
New +$38.2K ﹤0.01% 1135
2020
Q2 		– Sell
-791
Closed – – 2012
2020
Q1 		$0 Sell
791
-425
-35% -$579 ﹤0.01% 2301
2019
Q4 		$2K Sell
1,216
-3,379
-74% -$5.6K ﹤0.01% 1984
2019
Q3 		$5K Buy
4,595
+3,947
+609% +$5.6K ﹤0.01% 1743
2019
Q2 		$1K Sell
648
-1,015
-61% -$5.53K ﹤0.01% 1925
2019
Q1 		$10K Buy
1,663
+483
+41% +$3.2K ﹤0.01% 1232
2018
Q4 		$9K Buy
+1,180
New +$12.2K ﹤0.01% 1268
2017
Q2 		– Sell
-72
Closed -$2K – 1635
2017
Q1 		$2K Buy
+72
New +$2.08K ﹤0.01% 1339

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Meeder Asset Management's ACRS Position: Q4 2021 in Review

Meeder Asset Management sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 2,383 shares — an estimated $43K sold.

Meeder Asset Management first reported a position in ACRS in Q1 2017 and held it in 8 quarters. The position peaked at $43K in Q3 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • Meeder Asset Management reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Meeder Asset Management sold 2,383 Aclaris Therapeutics shares in Q4 2021, an estimated $43K.
  • Meeder Asset Management first reported a position in Aclaris Therapeutics in Q1 2017 and held it in 8 quarters.
  • Meeder Asset Management's Aclaris Therapeutics position peaked at $43K in Q3 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on Meeder Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.